Association of baseline microbiome and responders to immunotherapy for biochemically recurrent prostate cancer (BCR) without androgen deprivation therapy (ADT).Melissa Lauren Abel, Ravi A. Madan, Richard R. Rodrigues et al.|Journal of Clinical Oncology|2026Cited by 0
Short-course (3-month) enzalutamide monotherapy in biochemically recurrent prostate cancer (BCR): Preliminary prostate specific membrane antigen tumor volume (PSMA-TV) data.Aanika Warner, Melissa Lauren Abel, Laura A. Sena et al.|Journal of Clinical Oncology|2026Cited by 0